Table 4. Tyrosine kinase inhibitors in recurrent ovarian cancer.
| TKI | Site of action | RR | Median PFS (m) | Median OS (m) | Grade 3/4 toxicities |
|---|---|---|---|---|---|
| Sunitinib Biaji et al [36] |
VEGFR, PDGFR |
3.3% | 4.1 | – | Fatigue, hypertension, HFS, neutropenia |
| Sorafenib Mateo et al [37] |
VEGFR, PDGFR, Flt3, c kit, Raf | 3.4% | 2.1 | 16.33 | Rash, HFS, metabolic, cardiac and pulmonary toxicity. |
| Cediranib Matulonis et al [34] |
VEGFR, c kit | 17% | 5.2 | Not reached*
|
CNS haemorrhage, hypertriglyceridaemia and elevated creatinine. |
| Vandetanib** Harter P et al [39] |
VEGFR, EGFR, RET | 10% | 6.7 | 11.1 | Elevated liver enzymes, neutropenia, pulmonary embolism, mucositis. |
TKI: tyrosine kinase inhibitors; RR: response rates; PFS: progression-free survival; m: Months; OS: overall survival; HFS: hand foot syndrome.
*
Mean OS was 16.3 months.
**
Vandetanib was combined with liposomal doxorubicin 50 mg/m2 Q 28-day cycle.